Mushrooms for CTE: Preclinical Evidence and Speculation

Mushrooms & Brain Health / Cognition

1 tau model study

Rodriguez and Lippi (2022) is the only study testing a mushroom compound in a tau mouse model relevant to CTE pathology. Lion's mane reduced anxiety-like behaviors in rTg4510 mice. No CTE-specific animal model or human study exists.

Rodriguez & Lippi, Behavioral Sciences, 2022

Posthumous only

CTE can be definitively diagnosed only after death, which makes clinical trials nearly impossible without better biomarkers

Perivascular tau

the distribution pattern that distinguishes CTE tau accumulation from Alzheimer's, caused by repetitive head impacts

No approved treatment

for CTE exists; mushroom research has not advanced beyond mechanistic extrapolation and one adjacent animal study

Rodriguez & Lippi, Behavioral Sciences, 2022

View as image ↗

Chronic traumatic encephalopathy (CTE) is a neurodegenerative disease caused by repetitive head impacts, and it can only be diagnosed after death. There is no approved treatment. No drug has cleared a Phase III clinical trial for CTE. No mushroom compound has been tested in a CTE-specific animal model or in any human CTE population.

That context matters before discussing what does exist. The connection between mushrooms and CTE is not direct evidence; it is a chain of mechanistic reasoning built from adjacent science. Mushroom compounds reduce neuroinflammation; neuroinflammation drives tau propagation, which is the central pathological process in CTE. Lion's mane reduced behavioral consequences of tau pathology in a genetic tau mouse model. Mushroom compounds are being studied as candidates for neurodegenerative diseases that share CTE's molecular characteristics. Whether any of that will ever translate into a CTE-specific trial is unknown. This article separates what the evidence shows from what is extrapolation and what is outright speculation. For broader context on mushrooms and brain health research, see the complete guide to mushrooms and cognitive aging.

CTE at the Molecular Level: Why Tau Accumulation Makes It Different from Other Brain Diseases

Chronic traumatic encephalopathy is not simply a severe concussion. It is a distinct neurodegenerative disease with its own molecular signature.

In a healthy brain, tau proteins help stabilize the internal scaffolding of neurons. When tau becomes hyperphosphorylated (chemically modified in a specific way), it loses its stabilizing function and instead clumps together into tangles. In CTE, this abnormal tau accumulates in a specific pattern: clustered around small blood vessels in the brain's cortex, particularly at the tops of ridges on the brain's surface. Pathologists call this perivascular tau accumulation, and it is the defining feature that distinguishes CTE from Alzheimer's disease (which also involves tau, but distributed differently).

The trigger for this tau modification in CTE is mechanical: repeated impacts that stretch and damage axons, activate brain immune cells (microglia), and trigger an inflammatory cascade. This cascade promotes the chemical modification of tau, which then misfolds and spreads from neuron to neuron over years or decades. The damage is cumulative and slow-moving. Athletes who develop CTE typically do not show symptoms until years after their career ends.

The diagnostic barrier is absolute with current technology. There is no blood test and no brain scan that can definitively identify CTE in a living person. Research groups have identified patterns in tau PET imaging and certain protein levels in cerebrospinal fluid that correlate with CTE risk, but none of these have been validated as definitive diagnostic biomarkers. Diagnosis requires examination of brain tissue, which can only happen post-mortem.

This is why there are no approved CTE treatments. Running a treatment trial requires the ability to identify patients who have the disease, treat them, and measure whether treatment changed their disease trajectory. Without a living diagnostic tool, none of those steps is possible in the standard way. Researchers are working on this problem, but it has not been solved.

The Neuroinflammation Connection: Why Mushroom Researchers Have a Reason to Care About CTE

Despite the absence of CTE-specific mushroom research, there is a legitimate biological reason mushroom researchers might be interested in CTE, and vice versa.

Neuroinflammation is central to CTE progression. When head impacts damage brain tissue, microglia (the brain's resident immune cells) activate and release inflammatory signaling proteins called cytokines. This inflammatory response, which is useful for clearing damaged tissue in the short term, becomes problematic when it is chronic and repetitive. Sustained microglial activation promotes tau hyperphosphorylation and helps tau spread from cell to cell. In CTE, the inflammatory environment and the tau pathology reinforce each other.

Mushroom compounds have well-documented anti-neuroinflammatory activity across multiple molecular pathways. Erinacines (from lion's mane mycelium) activate the Nrf2 pathway, which is the cell's master switch for producing antioxidant enzymes. Cordycepin (from Cordyceps species) inhibits NF-kappaB, the master regulator of inflammatory gene expression, and suppresses the NLRP3 inflammasome, a key driver of the microglial inflammatory cascade. Multiple mushroom polysaccharides modulate microglial behavior to reduce inflammatory output.

The logical chain: if chronic neuroinflammation drives tau propagation, and mushroom compounds reduce neuroinflammation, then mushroom compounds might theoretically slow tau accumulation and spread. This is a reasonable hypothesis. It is not tested evidence.

Abitbol and colleagues published a review in Cells in 2022 examining mushroom natural products as drug discovery candidates for neurodegenerative diseases.^[1] Their review covers multiple mushroom species and mechanisms relevant to diseases sharing CTE's molecular features: tau pathology, neuroinflammation, oxidative stress, and protein aggregation. The drug discovery framing is meaningful. It places mushroom compounds in the context of serious academic interest in neurodegenerative disease, not wellness marketing.

For more on how mushroom compounds work against brain inflammation specifically, see mushroom compounds and brain inflammation after injury. For the deeper question of how mushrooms interact with tau protein in Alzheimer's disease research (CTE and Alzheimer's share tau pathology), see mushroom compounds and tau protein in Alzheimer's mechanisms.

The Closest Existing Evidence: Lion's Mane in a Tau Mouse Model

Rodriguez and Lippi, in a 2022 paper in Behavioral Sciences, tested lion's mane in the rTg4510 mouse model and found it produced anxiolytic effects: reductions in anxiety-like behavior characteristic of tau disease burden in this model.^[2] This is the study closest to CTE-relevant mushroom evidence that currently exists. Understanding what it does and does not show requires understanding the model.

Animal model — tau-driven behavior

Rodriguez & Lippi (2022) · Behavioral Sciences

Population

rTg4510 mice — a genetic tauopathy model (Alzheimer's-type, not CTE-specific)

Intervention

Diet supplemented with Hericium erinaceus (lion's mane) for ~4.5 months

Comparator

Standard rodent diet

Finding

Lion's mane produced anxiolytic effects, reducing the anxiety-like behavior that tracks tau disease burden in this model. It did not test — and does not establish — a reduction in tau protein itself, and the model's tau is genetically driven and brain-wide, not the impact-induced perivascular tau of CTE.

preliminary Meaningful signal that lion's mane can blunt the behavioral consequences of tauopathy in an animal, but the model is an Alzheimer's-type genetic tauopathy, not CTE. Anxiety is notable because it is among the earliest documented behavioral changes in human CTE — yet the CTE-specific test has not been done.

Rodriguez & Lippi, Behavioral Sciences, 2022

The rTg4510 is a genetically engineered mouse that carries mutations causing severe tau protein accumulation in the brain from an early age. It is commonly used to study tauopathy, which is the class of diseases defined by abnormal tau accumulation, including Alzheimer's disease, frontotemporal dementia, and CTE. In rTg4510 mice, tau builds up rapidly and massively, producing behavioral changes including anxiety, memory impairment, and reduced activity. The model is a useful research tool for testing whether compounds affect tau pathology and its behavioral consequences.

The rTg4510 is primarily an Alzheimer's research model, not a CTE model. The important differences: in rTg4510, tau accumulation is caused by genetic mutation, not by mechanical impacts; the tau distributes throughout the brain broadly, not in the perivascular pattern characteristic of CTE; and the speed and severity of tau accumulation far exceed what occurs in human CTE. CTE results from years of repeated impacts; rTg4510 mice develop severe tauopathy within months due to their genetic programming.

That gap does not erase the significance of the finding. It calibrates it. Rodriguez and Lippi showed that lion's mane can reduce behavioral impairment caused by tau-driven neurodegeneration in an animal model. That is meaningful data. It means lion's mane has some activity that interferes with the behavioral consequences of tauopathy. Whether that activity would operate on CTE-type tau accumulation, which develops differently and distributes differently, is an open question.

The anxiolytic effect is notable because anxiety and depression are among the earliest behavioral changes documented in human CTE cases. If lion's mane reduces anxiety in tau mice, the question of whether it might have similar effects in early-stage CTE is scientifically legitimate. The experimental answer is: not yet tested.

For the broader picture of how lion's mane behaves after head injury, see lion's mane after concussion: what the research shows and the broader TBI neuroprotection review at mushrooms for traumatic brain injury.

How Far Away Is Clinical Relevance? Brandalise's Bench-to-Bedside Assessment

Brandalise and colleagues published a systematic review in Journal of Fungi in 2023 examining the lion's mane evidence base for neurodegenerative diseases.^[3] The title of their paper is worth quoting directly: "Hericium erinaceus in Neurodegenerative Diseases: From Bench to Bedside and Beyond, How Far from the Shoreline?" The framing reveals the conclusion before the reader reaches the abstract.

Their review assessed two parallel tracks. The preclinical evidence base for lion's mane in neurodegenerative disease is substantive: NGF induction supporting neuron survival, erinacine-driven neuroprotection, anti-neuroinflammatory effects through multiple pathways, and behavioral improvements in multiple animal models of neural degeneration. Across these models, lion's mane consistently shows activity relevant to neurodegenerative disease processes. That is the bench.

The bedside track is thinner. Human clinical evidence consists primarily of small trials in mild cognitive impairment populations, with short follow-up periods and no established dosing protocol. The gap between what has been shown in animal models and what has been confirmed in human patients is large. For neurodegenerative diseases in general, Brandalise's conclusion is: the biology is promising but clinical confirmation is limited.

For CTE specifically, the gap is compounded by the diagnostic problem. Even if lion's mane were confirmed to reduce tau accumulation or neuroinflammation in animal models of CTE (which has not happened), designing a human CTE trial would require solving the living-biomarker problem first. Without a way to identify living CTE patients and track disease progression reliably, a clinical trial cannot be structured, and any observed effect cannot be attributed to the intervention rather than natural disease variation.

The shoreline Brandalise points to is not close.

Evidence, Extrapolation, and Speculation: How to Read Mushroom-CTE Claims

Consumer content about mushrooms and CTE tends to treat all three of these categories as equivalent. They are not, and the distinction matters for people making decisions about a disease that has devastated families.

Reading Mushroom–CTE Claims

Three Tiers of Honesty, From Evidence to Speculation

Consumer content tends to flatten these three categories into one. They are not the same. Bar width reflects how much direct support stands behind each tier — widest for the sourced facts at the bottom, collapsing toward the top, where marketing claims outrun the data entirely.

Established evidence

What has actually been shown?

Rodriguez 2022 · D’Amico 2021 · Abitbol 2022

Sourced facts: lion’s mane reduced tau-pathology-related anxiety in the rTg4510 genetic tau mouse (Rodriguez 2022); lion’s mane + turkey tail modulated neurodegenerative changes in a controlled cortical-impact TBI model (D’Amico 2021); mushroom compounds are under academic study as neurodegenerative-disease drug candidates (Abitbol 2022).

Scientific extrapolation

What might follow, in theory?

Mechanistic rationale — not yet tested

Reasonable, untested hypotheses: if chronic neuroinflammation drives tau propagation, and mushroom compounds reduce neuroinflammation, they might slow CTE-type tau accumulation. The kind of rationale researchers use to design a trial — not a result from one. No CTE-specific study has tested it.

Speculation without evidence

What marketing asserts anyway

No CTE evidence exists

Claims that mushrooms prevent CTE, treat CTE, or that a specific supplement protects athletes from developing it. No mushroom compound has been tested in a CTE-specific animal model or in any human CTE population — these statements go beyond what any evidence supports.

How to read it: only the bottom tier can be stated and sourced. The middle tier is honest speculation — a hypothesis worth testing, phrased as a hypothesis. The top tier is where hope-based marketing lives: it treats untested rationale as established fact. For a disease that can only be diagnosed after death, that distinction protects the families most likely to be sold on it.

Sources: Abitbol 2022 [1]; Rodriguez & Lippi 2022 [2]; D’Amico 2021 [4]. Bar widths are illustrative of evidence depth and specificity, not quantitative effect sizes. No CTE-specific mushroom study exists as of publication.

Established evidence in this space covers several things. Mushroom compounds (erinacines, cordycepin, beta-glucans) reduce neuroinflammatory markers across multiple animal models. Lion's mane activates the Nrf2 antioxidant pathway and crosses the blood-brain barrier. Lion's mane reduced tau-pathology-related anxiety in a genetic tau mouse model (Rodriguez 2022). In a controlled cortical impact model of traumatic brain injury, lion's mane combined with turkey tail (Coriolus versicolor) modulated the molecular and biochemical changes tied to the Parkinson's-type neurodegeneration that TBI can trigger (D'Amico 2021).^[4] Mushroom compounds are under academic investigation as neurodegenerative disease drug candidates (Abitbol 2022). These statements can be made and sourced.

Scientific extrapolation occupies the next tier. If neuroinflammation drives CTE progression, and mushroom compounds reduce neuroinflammation, they might slow CTE. If lion's mane reduces behavioral consequences in a tau mouse model, it might reduce behavioral consequences in early CTE. Mushroom compounds have already blunted the neurodegenerative cascade after traumatic brain injury in a controlled cortical impact model (D'Amico 2021); the untested leap is whether that same protection would slow the distinct, tau-driven sequence that turns years of repeated impacts into CTE. These are reasonable hypotheses, the kind researchers use to design trials. None of the CTE-specific versions have been tested.

Speculation without evidence covers anything that treats those hypotheses as established facts. Claims that mushrooms prevent CTE. Claims that mushrooms treat CTE. Claims that athletes should take a specific mushroom supplement to protect against CTE development. These go beyond what the evidence supports.

The distinction is not pedantic. Families of athletes diagnosed posthumously with CTE are specifically vulnerable to hope-based claims in the absence of effective treatments. The honest answer is: there is mechanistic rationale for studying mushrooms in CTE. The studies do not exist. The rationale for doing those studies is sound. The results of those studies are unknown.

Consumer claims & CTE

Moderate

No mushroom supplement has been shown to prevent or treat CTE

Concern

Because CTE has no approved treatment and can only be confirmed after death, families and athletes are uniquely exposed to marketing that presents untested mechanistic rationale as if it were proven protection. No mushroom compound has been tested in a CTE-specific animal model or human CTE population.

What the research says

Treat 'mushrooms prevent CTE' and 'mushrooms treat CTE' as unsupported claims. The honest state of the science is a plausible research hypothesis, not a usable intervention. Nothing here is medical advice.

Particularly relevant for: Athletes, veterans, and families affected by repetitive head impacts

What to do

Discuss any supplement, symptom, or head-injury history with a qualified physician or neurologist rather than relying on wellness marketing.

Article synthesis; no CTE-specific mushroom trial exists as of publication

The Bottom Line

CTE is a tau protein accumulation disease caused by repetitive head impacts, diagnosed only at autopsy, and with no approved treatment. The connection between mushrooms and CTE rests on adjacent science, not direct evidence: mushroom compounds reduce neuroinflammation (which drives tau propagation), and lion's mane reduced anxiety-like behavior in a genetic tau mouse model (Rodriguez 2022) that shares tau pathology with CTE but is not a CTE-specific model. No mushroom compound has been tested in a CTE-specific animal model or human population. Brandalise's 2023 bench-to-bedside review identifies the wide gap between preclinical promise and clinical validation for lion's mane in neurodegenerative disease broadly; for CTE, that gap is wider still.

Frequently Asked Questions

Can mushrooms help prevent CTE?

No evidence shows that any mushroom compound prevents CTE in humans. The mechanistic case rests on mushrooms reducing neuroinflammation, which drives the tau propagation that characterizes CTE, but this connection has not been tested in a CTE-specific animal model or human study. The only adjacent animal evidence is Rodriguez and Lippi (2022), who found lion's mane reduced anxiety-like behavior in a genetic tau mouse model, which is not the same as a CTE model.

Is there any research on natural treatments for CTE?

There are no clinical trials of any natural treatment specifically for CTE. The fundamental barrier is diagnostic: CTE cannot be definitively confirmed in living patients, making it extremely difficult to design and measure outcomes in a treatment trial. Research on natural compounds that might theoretically address CTE's pathology (neuroinflammation, tau accumulation, oxidative stress) is ongoing in adjacent disease models, but none of this research has specifically targeted CTE-model animals or CTE-confirmed human patients.

What is CTE and can it be treated?

Chronic traumatic encephalopathy (CTE) is a neurodegenerative disease caused by repetitive head impacts, characterized by perivascular accumulation of hyperphosphorylated tau protein in the brain's cortex. It progresses slowly, often not producing symptoms until decades after the causative head impacts. CTE can currently only be diagnosed after death by examining brain tissue. There is no approved treatment for CTE. Research on biomarkers for living diagnosis and on potential therapeutic targets (including tau and neuroinflammation pathways) is active.

Does lion's mane reduce tau protein?

In a genetic tau mouse model (rTg4510), lion's mane reduced anxiety-like behaviors associated with tau pathology (Rodriguez & Lippi, 2022). Whether lion's mane directly reduces tau protein levels or accumulation in that model, or in any CTE-relevant model, is not established from the available data. Mechanistically, lion's mane reduces neuroinflammation, which promotes tau hyperphosphorylation and spreading, so an indirect effect on tau burden through inflammation reduction is plausible but not confirmed in CTE-specific research.

What causes CTE at the molecular level?

Repetitive head impacts trigger mechanical damage to axons, activating microglia (the brain's immune cells). Sustained microglial activation promotes the hyperphosphorylation of tau protein, which causes tau to misfold and aggregate into tangles rather than supporting neuron structure. These tau tangles accumulate in a characteristic perivascular (around small blood vessels) pattern in the cortex. The tau spreads progressively from neuron to neuron, driving neurodegeneration. Chronic neuroinflammation and tau propagation reinforce each other over years, explaining why CTE symptoms often appear long after the impacts that triggered the disease.

Sources & References

1. 1RTHM-00737·Abitbol, Arjuna et al. (2022). “Mushroom Natural Products in Neurodegenerative Disease Drug Discovery..” Cells.Study breakdown →PubMed →↩
2. 2RTHM-01610·Rodriguez, Mya N et al. (2022). “Lion's Mane (Hericium erinaceus) Exerts Anxiolytic Effects in the rTg4510 Tau Mouse Model..” Behavioral sciences (Basel.Study breakdown →PubMed →↩
3. 3RTHM-01662·Brandalise, Federico et al. (2023). “Hericium erinaceus in Neurodegenerative Diseases: From Bench to Bedside and Beyond, How Far from the Shoreline?.” Journal of fungi (Basel.Study breakdown →PubMed →↩
4. 4RTHM-01340·D'Amico, Ramona et al. (2021). “Hericium erinaceus and Coriolus versicolor Modulate Molecular and Biochemical Changes after Traumatic Brain Injury..” Antioxidants (Basel.Study breakdown →PubMed →↩